Brand Zepbound lists around $1,089 per month at retail. Real-world cash cost ranges from $25 with commercial insurance plus the savings card, to $50 on the Medicare GLP-1 Bridge, to roughly $299–$449 for LillyDirect self-pay vials, to $99–$299 for compounded tirzepatide.
On this page
The savings card route: $25
Eli Lilly's Zepbound Savings Card can reduce your cost to as little as $25 per month — but only if you have commercial insurance that actually covers Zepbound for chronic weight management. If your plan excludes weight-loss drugs, the card typically brings the list price down to roughly $650, not $25.
Federal law prohibits manufacturer copay assistance for people on Medicare or Medicaid. If you are on either, the card is unavailable to you regardless of income.
LillyDirect self-pay vials: $299–$449
Eli Lilly sells single-dose Zepbound vials directly to cash-paying patients. Pricing is tiered by strength — $299 per month at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above with a refill inside 45 days. You need a prescription from your own clinician; LillyDirect fulfills it rather than prescribing.
There is no subscription. Each fill is a separate order, which makes it the most flexible brand route and the easiest to stop.
Medicare GLP-1 Bridge: $50
The demonstration launched on 1 July 2026 at a $50 monthly copay for eligible Part D enrollees, covering Wegovy, Zepbound and Foundayo. Eligibility tiers are stricter than the headlines suggested: broadly BMI ≥35, or ≥30 with heart failure, hypertension or chronic kidney disease, or ≥27 with prediabetes or prior cardiovascular event. Your prescriber submits the request — you cannot.
The Mounjaro route most people miss
Mounjaro is the identical molecule with a type 2 diabetes label. If you have a type 2 diabetes diagnosis and commercial insurance, the Mounjaro savings card can bring you to $25 per month. This is not a workaround to engineer — it is a reminder to check whether you already qualify.
Compounded: $99–$299
The same active molecule from a licensed US compounding pharmacy, at roughly one-tenth of retail. Not FDA-approved, and the quality assurance rests on the pharmacy rather than on FDA review. Our provider index lists what each program discloses about its pharmacy partner.
Common questions
Can I switch from semaglutide to tirzepatide without starting over?
You restart at 2.5 mg tirzepatide regardless of your semaglutide dose, because there is no equivalence between the molecules. Most switchers find re-titration far easier than a first start — roughly 13% report GI symptoms — because GLP-1 receptor adaptation carries over. Take the first tirzepatide dose about seven days after your last semaglutide injection.
Why is some tirzepatide advertised under $100 a month?
Usually one of four reasons: it is the 2.5 mg starter-tier price only, it is an introductory rate that reverts, there is a separate membership fee, or the product is not from a licensed US pharmacy. Ask what you will pay at 10 mg before you enrol.
What is the difference between a 503A and a 503B pharmacy?
A 503A pharmacy compounds for an identified individual patient with a prescription and is licensed by a state board of pharmacy. A 503B outsourcing facility registers with FDA, may compound in bulk without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. Most compounded tirzepatide now flows through the 503A pathway.
How much does tirzepatide cost per month without insurance?
Compounded tirzepatide from licensed US telehealth programs runs roughly $99 to $299 per month depending on the provider and whether the price is flat or scales with your dose. Brand-name Zepbound through LillyDirect self-pay runs about $299 to $449 per month depending on strength. Retail Zepbound without any program is around $1,089.
People also ask about zepbound cost
What is zepbound cost?
Zepbound cost is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does zepbound cost apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does zepbound cost cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is zepbound cost FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.